Amicus Therapeutics, Inc. (FOLD) — Financial statements
Income statement, balance sheet, and cash flow for Amicus Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 634↑20.0% | 528↑32.3% | 399↑21.3% | 329↑7.8% | 306 | |
| Cost of Revenue | 80↑51.8% | 53↑41.8% | 37↓3.3% | 39↑12.0% | 34 | |
| Gross Profit | 554↑16.5% | 475↑31.3% | 362↑24.6% | 291↑7.2% | 271 | |
| Operating Expenses | ||||||
| R&D Expenses | 136↑24.2% | 109↓28.2% | 152↓44.9% | 277↑1.7% | 272 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 383↑18.6% | 323↑17.5% | 275↑29.2% | 213↑10.6% | 193 | |
| Other Expenses | 0.00↓100.0% | 18↑53.0% | 12↓11.1% | 13↑2.5% | 13 | |
| Operating Expenses | 519↑15.3% | 450↑2.6% | 439↓12.6% | 503↑5.3% | 477 | |
| Total Costs & Expenses | 600↑19.1% | 503↑5.6% | 477↓12.0% | 541↑5.7% | 512 | |
| Operating Results | ||||||
| Operating Income | 34↑38.7% | 25↑132.2% | -77↑63.6% | -212↓2.8% | -206 | |
| Depreciation & Amortization | 7↓12.7% | 9↑8.6% | 8↑47.4% | 5↓14.0% | 6 | |
| EBITDA | 54↑83.1% | 29↑131.9% | -92↑53.9% | -200↑1.6% | -203 | |
| EBIT | 46↑122.4% | 21↑120.9% | -100↑51.2% | -205↑2.0% | -209 | |
| Interest & Other Income | ||||||
| Net Interest Income | -43↑3.1% | -44↓2.6% | -43↓26.3% | -34↓6.7% | -32 | |
| Interest Income | 3↓38.7% | 5↓23.6% | 7↑134.1% | 3↑494.1% | 0.51 | |
| Interest Expense | 46↓6.9% | 50↓1.1% | 50↑35.1% | 37↑14.3% | 32 | |
| Non-Operating Income | -12↓394.0% | 4↓82.3% | 23↑415.8% | -7↓371.8% | 3 | |
| Other Income / Expenses | -34↑36.0% | -54↑26.4% | -73↓143.6% | -30↑14.8% | -35 | |
| Income Before Tax | 0.19↑100.7% | -29↑80.8% | -150↑38.0% | -242↓0.2% | -242 | |
| Income Tax Expense | 27↓0.2% | 27↑1744.2% | 1↑127.1% | -5↓161.4% | 9 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -27↑51.7% | -56↑63.0% | -152↑35.9% | -237↑5.5% | -250 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -27↑51.7% | -56↑63.0% | -152↑35.9% | -237↑5.5% | -250 | |
| Bottom-Line Net Income | -27↑51.7% | -56↑63.0% | -152↑35.9% | -237↑5.5% | -250 | |
| EPS (Basic) | -0.09↑51.2% | -0.18↑64.7% | -0.51↑37.8% | -0.82↑10.9% | -0.92 | |
| EPS (Diluted) | -0.09↑51.2% | -0.18↑64.7% | -0.51↑37.8% | -0.82↑10.9% | -0.92 | |
| Weighted Average Shares | 308↑1.3% | 304↑3.1% | 295↑2.1% | 289↑6.5% | 271 | |
| Weighted Average Diluted Shares | 308↑1.3% | 304↑3.1% | 295↑2.1% | 289↑6.5% | 271 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.